Loading
A phase 1/2 trial of GFH375, Cetuximab, Paclitaxel / nab-paclitaxel in colorectal cancer, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT07259590 by Genfleet Therapeutics (Shanghai) Inc., with 126 participants planned, started 2025-10-21 and due to reach its primary completion in 2027-07. Interventions recorded: GFH375, GFH375. Conditions listed: Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GFH375, GenFleet Therapeutics.
Shares GFH375, GenFleet Therapeutics.
Shares KRAS G12C-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colorectal cancer.
Shares GFH375, GenFleet Therapeutics.
Shares GFH375, GenFleet Therapeutics.
Shares Cetuximab, Paclitaxel / nab-paclitaxel, Gemcitabine, Colorectal cancer.
Shares KRAS G12C-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colorectal cancer.
Shares GenFleet Therapeutics, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/